Table 3.
Results of linear mixed effects models estimating the effect of clinician characteristics and microbial keratitis (MK) scenarios on the reported risk threshold to always or never treat with targeted medication.
| “Never” Treat | “Always” Treat | ||||||
|---|---|---|---|---|---|---|---|
| Term | Contrast | Effect | 95% CI | Holm-adjusted P-value | Effect | 95% CI | Holm-adjusted P-value |
| Experience (Years) | - | 0.1 | −0.01, 0.3 | 0.072 | −0.2 | −0.7, 0.3 | 0.46 |
| Gender | Male vs Female | −0.6 | −4.0, 2.9 | 0.754 | −7.1 | −18.5, 4.3 | 0.216 |
| MK Size & Location | <2mm2 Central vs >8mm2 Central | 1.2 | −0.2, 2.6 | 0.043 | 6.8 | 4.5, 9.2 | <0.001 |
| <2mm2 Peripheral vs >8mm2 Central | 2.9 | 1.4, 4.3 | <0.001 | 12.1 | 9.7, 14.4 | <0.001 | |
| <2mm2 Peripheral vs <2mm2 Central | 1.6 | 0.2, 3.1 | 0.012 | 5.2 | 2.8, 7.6 | <0.001 | |
| MK Type x Practice Location | Comparison between MK Type in US | ||||||
| F vs B | 8.4 | 2.1, 14.7 | 0.001 | 26.2 | 10.9, 41.5 | <0.001 | |
| H vs B | 5.4 | −0.3, 11.1 | 0.078 | 9.3 | −1.1, 19.7 | 0.097 | |
| H vs F | −3.0 | −8.4, 2.5 | 1 | −16.9 | −31.0, −2.8 | 0.005 | |
| A vs B | 10.9 | 3.3, 18.4 | <0.001 | 37.3 | 22.1, 52.6 | <0.001 | |
| A vs F | 2.5 | −3.5, 8.5 | 1 | 11.1 | 2.1, 20.2 | 0.004 | |
| A vs H | 5.4 | −0.7, 11.6 | 0.131 | 28.0 | 14.4, 41.6 | <0.001 | |
| Comparison between MK Type for Intl. | |||||||
| F vs B | 1.8 | −5.9, 9.4 | 1 | 4.6 | −14.0, 23.2 | 1 | |
| H vs B | 3.6 | −3.3, 10.6 | 1 | 2.8 | −9.8, 15.5 | 1 | |
| H vs F | 1.9 | −4.7, 8.5 | 1 | −1.7 | −18.9, 15.4 | 1 | |
| A vs B | 4.2 | −4.9, 13.4 | 1 | 7.2 | −11.4, 25.7 | 1 | |
| A vs F | 2.5 | −4.8, 9.7 | 1 | 2.6 | −8.4, 13.6 | 1 | |
| A vs H | 0.6 | −6.9, 8.1 | 1 | 4.4 | −12.2, 20.9 | 1 | |
| Comparison of Intl. vs US for each MK Type | |||||||
| B | 2.5 | −4.2, 9.2 | 1 | 20.5 | −3.5, 44.5 | 0.133 | |
| F | −4.1 | −15.3, 7.1 | 1 | −1.1 | −27.1, 24.9 | 1 | |
| H | 0.7 | −9.9, 11.3 | 1 | 14.0 | −10.3, 38.4 | 0.978 | |
| A | −4.1 | −17.7, 9.5 | 1 | −9.7 | −35.1, 15.8 | 1 | |
| Remaining Comparison | |||||||
| B Intl. vs F US | −5.9 | −14.5, 2.8 | 0.736 | −5.7 | −30.2, 18.8 | 1 | |
| B Intl. vs H US | −2.9 | −11.3, 5.5 | 1 | 11.2 | −12.8, 35.2 | 1 | |
| B Intl. vs A US | −8.4 | −18.3, 1.6 | 0.198 | −16.8 | −41.1, 7.5 | 0.483 | |
| F Intl. vs B US | 4.3 | −5.3, 13.8 | 1 | 25.1 | 0.2, 50.0 | 0.037 | |
| F Intl. vs H US | −1.1 | −12.0, 9.7 | 1 | 15.8 | −9.3, 40.9 | 0.735 | |
| F Intl. vs A US | −6.6 | −18.7, 5.5 | 1 | −12.3 | −37.9, 13.4 | 1 | |
| H Intl. vs B US | 6.1 | −3.0, 15.3 | 0.736 | 23.3 | −0.7, 47.4 | 0.05 | |
| H Intl. vs F US | −2.2 | −13.0, 8.5 | 1 | −2.9 | −27.6, 21.9 | 1 | |
| H Intl. vs A US | −4.7 | −16.5, 7.1 | 1 | −14.0 | −38.6, 10.6 | 0.983 | |
| A Intl. vs B US | 6.7 | −4.5, 18.0 | 1 | 27.7 | 3.1, 52.3 | 0.011 | |
| A Intl. vs F US | −1.6 | −14.2, 11.0 | 1 | 1.5 | −24.1, 27.0 | 1 | |
| A Intl. vs H US | 1.3 | −11.1, 13.7 | 1 | 18.4 | −6.4, 43.2 | 0.343 | |
| Practice Type | Private vs Academic | −2.8 | −9.4, 3.8 | 0.49 | 2.2 | −19.3, 23.6 | 1 |
| Hybrid vs Academic | −5.7 | −12.7, 1.3 | 0.119 | −15.9 | −38.7, 7.0 | 0.377 | |
| Other vs Academic | 8.7 | −3.0, 20.5 | 0.14 | 3.6 | −34.6, 41.8 | 1 | |
| Hybrid vs Private | −2.9 | −11.0, 5.2 | 0.49 | −18.0 | −44.4, 8.4 | 0.377 | |
| Other vs Private | 11.6 | −1.0, 24.2 | 0.075 | 1.4 | −39.6, 42.5 | 1 | |
| Other vs Hybrid | 14.5 | 2.3, 26.6 | 0.012 | 19.5 | −20.3, 59.2 | 0.746 | |
B=Bacterial; F=Fungal; H= Herpetic; A=Acanthamoeba; Intl=International; US = United States; CI, Confidence Interval